CORTRIL (hydrocortisone acetate) by Pfizer is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Approved for atopic dermatitis.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
CORTRIL is a hydrocortisone acetate injectable corticosteroid indicated for atopic dermatitis as an adjunctive anti-inflammatory therapy. It works by suppressing immune-mediated inflammatory responses through corticosteroid receptor activation. The product is currently in pre-launch stage under Pfizer's sponsorship.
Pre-launch stage offers entry point for brand-building roles, though market positioning against JAK inhibitors and IL-13 antagonists remains unclear until launch data emerges.
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
CORTRIL represents a pre-launch opportunity in a mature, competitive indication where commercial success will depend heavily on positioning against entrenched JAK inhibitors and novel mechanisms. Career advancement will be challenging given the product's traditional mechanism, patent vulnerability, and limited clinical differentiation in a crowded market.
Worked on CORTRIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo